Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)

• Published in: Annals of oncology Vol. 26; no. 8; pp. 1677 - 1684
• Main Authors: Launay-Vacher, V., Aapro, M., De Castro, G., Cohen, E., Deray, G., Dooley, M., Humphreys, B., Lichtman, S., Rey, J., Scotté, F., Wildiers, H., Sprangers, B.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2015
• Subjects: Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors - adverse effects; Antineoplastic Agents - adverse effects; cancer; ErbB Receptors - antagonists & inhibitors; Humans; kidney disease; Kidney Diseases - chemically induced; molecular targeted therapy; Molecular Targeted Therapy - adverse effects; nephrotoxicity; Protein Kinase Inhibitors - adverse effects; Proto-Oncogene Proteins B-raf - antagonists & inhibitors; RANK Ligand - antagonists & inhibitors; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Receptor, ErbB-2 - antagonists & inhibitors; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors; renal failure; renal toxicity; TOR Serine-Threonine Kinases - antagonists & inhibitors; renal failure; kidney disease; renal toxicity; molecular targeted therapy; cancer; nephrotoxicity
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdv136

A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic, including targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here, we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to vascular endothelial growth factor or VEGF receptor(s) (VEGF/VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor2 (HER2), BRAF, anaplastic lymphoma kinase (ALK), programmed cell death protein-1 or its ligand (PD-1/PDL-1), receptor activator of nuclear factor kappa-B ligand (RANKL), and mammalian target of rapamycin (mTOR). The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.